- Home
- HAFN vs HCM Comparison
HAFN vs HCM Comparison
Compare HAFN & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HAFN
- HCM
- Stock Information
- Founded
- HAFN 2012
- HCM 2000
- Country
- HAFN Bermuda
- HCM Hong Kong
- Employees
- HAFN N/A
- HCM N/A
- Industry
- HAFN
- HCM Biotechnology: Pharmaceutical Preparations
- Sector
- HAFN
- HCM Health Care
- Exchange
- HAFN Nasdaq
- HCM Nasdaq
- Market Cap
- HAFN 2.8B
- HCM 2.6B
- IPO Year
- HAFN N/A
- HCM N/A
- Fundamental
- Price
- HAFN $5.44
- HCM $14.20
- Analyst Decision
- HAFN Strong Buy
- HCM Hold
- Analyst Count
- HAFN 2
- HCM 1
- Target Price
- HAFN $8.25
- HCM $19.00
- AVG Volume (30 Days)
- HAFN 2.5M
- HCM 77.7K
- Earning Date
- HAFN 02-27-2025
- HCM 02-26-2025
- Dividend Yield
- HAFN 27.92%
- HCM N/A
- EPS Growth
- HAFN N/A
- HCM N/A
- EPS
- HAFN 1.69
- HCM N/A
- Revenue
- HAFN $3,039,225,000.00
- HCM $610,806,000.00
- Revenue This Year
- HAFN N/A
- HCM N/A
- Revenue Next Year
- HAFN N/A
- HCM $20.69
- P/E Ratio
- HAFN $3.21
- HCM N/A
- Revenue Growth
- HAFN 15.24
- HCM N/A
- 52 Week Low
- HAFN $4.99
- HCM $11.93
- 52 Week High
- HAFN $8.99
- HCM $21.92
- Technical
- Relative Strength Index (RSI)
- HAFN N/A
- HCM 42.32
- Support Level
- HAFN N/A
- HCM $13.00
- Resistance Level
- HAFN N/A
- HCM $15.29
- Average True Range (ATR)
- HAFN 0.00
- HCM 0.46
- MACD
- HAFN 0.00
- HCM -0.00
- Stochastic Oscillator
- HAFN 0.00
- HCM 37.74
About HAFN Hafnia Limited Common Shares
Hafnia Ltd is one of the tanker owners, transporting oil, oil products and chemicals for national and international oil companies, chemical companies, as well as trading and utility companies. As owners and operators of around 200 vessels, It offers a fully integrated shipping platform, including technical management, commercial and chartering services, pool management, and a large-scale bunker procurement desk.
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is an innovative biopharmaceutical company engaged in the discovery, global development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.